Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  EXACT Sciences Corporation    EXAS

EXACT SCIENCES CORPORATION

(EXAS)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Exact Sciences in advanced talks to buy Genomic Health for $2.8 billion: Bloomberg

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/27/2019 | 07:09pm EDT
Exact Sciences Laboratories building is shown in Madison, Wisconsin

(Reuters) - Cancer diagnostics company Exact Sciences Corp is in advanced negotiations to buy healthcare company Genomic Health Inc for about $2.8 billion to strengthen its cancer testing, Bloomberg reported on Saturday.

A deal could be announced as early as next week but the talks could still be delayed or fall apart altogether, according to the report, which cited people familiar with the matter.

Exact Sciences and Genomic Health did not respond immediately to a Reuters request for comment on Saturday.

(Reporting by Kanishka Singh in Bengaluru; Editing by Sonya Hepinstall)

Stocks mentioned in the article
ChangeLast1st jan.
EXACT SCIENCES CORPORATION 1.64% 117.92 Delayed Quote.86.88%
GENOMIC HEALTH, INC. 5.55% 68.66 Delayed Quote.6.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EXACT SCIENCES CORPORATION
07/27EXACT SCIENCES IN ADVANCED TALKS TO : Bloomberg
RE
07/26EXACT SCIENCES CORP : Entry into a Material Definitive Agreement, Change in Dire..
AQ
07/09EXACT SCIENCES : to host annual meeting, second-quarter 2019 results webcasts an..
PU
06/26EXACT SCIENCES : Advances Fight Against Colorectal Cancer With Opening Of New La..
PU
06/24EXACT SCIENCES : EMET Prize announces new cadre of winners
AQ
06/18EXACT SCIENCES : WEDC determines Exact Sciences doesn't owe anything
AQ
05/31EXACT SCIENCES : to participate in June investor conferences
PU
05/20EXACT SCIENCES : Advances Pipeline Capabilities with Mayo Clinic
PU
05/17EXACT SCIENCES : Presents New Data Reinforcing Performance of Cologuard®
PU
05/03EXACT SCIENCES : starts to see payoff from Pfizer marketing tie-up
AQ
More news
Financials (USD)
Sales 2019 747 M
EBIT 2019 -240 M
Net income 2019 -282 M
Finance 2019 195 M
Yield 2019 -
P/E ratio 2019 -53,5x
P/E ratio 2020 -102x
EV / Sales2019 20,1x
EV / Sales2020 13,9x
Capitalization 15 228 M
Chart EXACT SCIENCES CORPORATION
Duration : Period :
EXACT Sciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 121,90  $
Last Close Price 117,92  $
Spread / Highest target 18,7%
Spread / Average Target 3,38%
Spread / Lowest Target -9,26%
EPS Revisions
Managers
NameTitle
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey T. Elliott Chief Financial Officer
Barry M. Berger Co-Chief Medical Officer & Head-Medical Affairs
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
EXACT SCIENCES CORPORATION86.88%15 228
IQVIA HOLDINGS INC37.63%31 320
LONZA GROUP35.69%25 668
CELLTRION, INC.--.--%19 960
INCYTE CORPORATION26.04%17 187
SEATTLE GENETICS, INC.31.42%12 574